share_log

OraSure to Announce First Quarter 2024 Financial Results and Host Earnings Call on May 8th

OraSure to Announce First Quarter 2024 Financial Results and Host Earnings Call on May 8th

OraSure將於5月8日公佈2024年第一季度財務業績並舉辦業績電話會議
GlobeNewswire ·  04/22 20:00

BETHLEHEM, Pa., April 22, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering first quarter 2024 financial results and certain business developments for 4:45 p.m. ET on Wednesday, May 8, 2024.

賓夕法尼亞州伯利恒,2024年4月22日(GLOBE NEWSWIRE)——OraSure Technologies, Inc.(納斯達克股票代碼:OSUR)計劃在美國東部時間2024年5月8日星期三下午4點45分舉行定期業績電話會議,涵蓋2024年第一季度的財務業績和某些業務發展。

A webcast of the conference call will be available on the investor relations page of OraSure's website at Please click on the webcast link and follow the prompts for registration and access at least 10 minutes prior to the call. The webcast will be archived on OraSure's website shortly after the call has ended and will be available for approximately 90 days.

電話會議的網絡直播將在OraSure網站的投資者關係頁面上播出,請點擊網絡直播鏈接,在電話會議開始前至少10分鐘按照提示進行註冊和訪問。電話會議結束後不久,網絡直播將存檔在OraSure的網站上,並將持續約90天。

To participate in the live conference call, please follow the link below to pre-register. After registering, you will be provided with access details via email.

要參加實時電話會議,請點擊以下鏈接進行預註冊。註冊後,將通過電子郵件向您提供訪問詳細信息。

About OraSure Technologies, Inc.
OraSure Technologies (the "Company") transforms health through actionable insight and powers the shift that connects people to healthcare wherever they are. The Company improves access, quality, and value of healthcare with innovation in effortless tests, sample management solutions, and services. OraSure, together with its wholly-owned subsidiaries, DNA Genotek, Diversigen, and Novosanis, provides its customers with end-to-end solutions that encompass diagnostics, tools, and services. The OraSure family of companies is a leader in the development, manufacture, and distribution of rapid diagnostic tests, sample collection and stabilization devices, and molecular services solutions designed to discover and detect critical medical conditions. OraSure's portfolio of products is sold globally to clinical laboratories, hospitals, physician's offices, clinics, public health and community-based organizations, research institutions, government agencies, pharmaceutical companies, commercial entities, and direct to consumers. For more information on OraSure Technologies, please visit .

關於 OraSure Technologies, Inc
OraSure Technologies(“公司”)通過切實可行的見解改變健康狀況,推動人們無論身在何處都能獲得醫療保健的轉變。該公司通過在輕鬆測試、樣本管理解決方案和服務方面的創新,改善了醫療保健的可及性、質量和價值。OraSure及其全資子公司DNA Genotek、Diversigen和Novosanis爲其客戶提供包括診斷、工具和服務的端到端解決方案。OraSure家族公司在開發、製造和分銷快速診斷檢測、樣本採集和穩定設備以及旨在發現和檢測關鍵疾病的分子服務解決方案方面處於領先地位。OraSure的產品組合在全球範圍內銷售給臨床實驗室、醫院、醫生辦公室、診所、公共衛生和社區組織、研究機構、政府機構、製藥公司、商業實體,並直接銷售給消費者。有關 OraSure 科技的更多信息,請訪問。

Investor Contact: Media Contact:
Jason Plagman Amy Koch
VP, Investor Relations Director, Corporate Communications
investorinfo@orasure.com media@orasure.com
投資者聯繫人: 媒體聯繫人:
傑森·普拉格曼 艾米·科赫
投資者關係副總裁 企業傳播總監
investorinfo@orasure.com media@orasure.com

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論